PTGX · Protagonist Therapeutics, Inc

Track PTGX — free

$140.06 +0.87 (+0.63%) At close · Oct 2

S&P 600 member Russell 2000 member Rebalance outlook locked

Market Cap

$9.18B

64.71M

Volume · Oct 2 760.3K Avg daily vol (3M) 634.39K

Up next

Next earnings call

Mar 21, 2027 Est · unconfirmed · in 24 wks

Latest filing: 10-Q

filed Aug 5, 2026

Q4 2020 earnings call transcript

call held Mar 10, 2021

Metrics snapshot

Useful current figures from the complete screener profile.

View all 115 metrics

Revenue (TTM)

$281.99M

Trailing 12 months

Net income (TTM)

$82.91M

Trailing 12 months

Revenue growth YoY

+3,749.2%

Year over year

Operating margin

20.7%

Trailing 12 months

P / E (TTM)

136.0

Trailing earnings · reciprocal yield 0.7%

FCF yield

1.4%

TTM · current market cap

Return on invested capital

—

Trailing 12 months

Net cash

—

Latest balance sheet

Dividend yield

—

Trailing 12 months

Shares change YoY

+11.8%

Year over year · more shares

Price change (1Y)

+115.5%

Trailing year

Short interest

12.6%

Latest settlement · 15.1 days to cover

View all 115 metrics

Equibles Rating

blended score · not investment advice

Overall

Neutral

SellHoldBuy

Technical Neutral Momentum Strong Sentiment Neutral Fundamentals Weak Quant / Vol High

Market backdrop VIX 15.3 · calm Equity put/call 0.58

Technical

price trend

Neutral

50 / 200-day cross No cross

Price vs 200-day avg +26%

above

Price vs 50-day avg −3%

below

RSI (14) 44

neutral

MACD trend Negative

52-week position 80%

mid-range

Volume (OBV) Confirms

volume backs price

Momentum

relative strength

Strong

1-month return −6%

trailing

6-month return +44%

trailing

YTD return +60%

this year

Relative strength +31%

vs S&P · 6-mo

Sentiment

smart money

Neutral

Trend (MA cross) No cross

50d $145 › 200d $111 — 50d above 200d

Institutional flow Accumulating

2 of 346 funds reported for Sep 30 · net +5 sh shares

Insider flow Flat

No net insider activity over 90 days

Short interest Rising

12.58% of float · ▲ +5.5% MoM · 15.1 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

346 holders — near 3-yr high, broad support

Squeeze score 85

high risk · 0–100

Fundamentals

Weak

Revenue growth −89%

Y/Y

EPS growth −148%

Y/Y

Free cash flow $56.1M

Valuation P/E 137.7

rich

Balance sheet $23.2M

net cash

Quant / Vol

risk profile

High

Volatility 50%

annualized · 1-yr

Max drawdown −16%

past year

ATR 3.6%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Neutral

1 · 5 · 1

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

+26% Bullish

Price vs 50-day avg

−3% Neutral

RSI (14)

44 Neutral

MACD trend

Negative Bearish

52-week position

80% Neutral

Volume (OBV)

Confirms Neutral

Market signals — smart money & positioning

Bullish · 2 of 6

Trend (MA cross) No cross

50d $145 › 200d $111 — 50d above 200d

Institutional flow Accumulating

2 of 346 funds reported for Sep 30 · net +5 sh shares

Insider flow Flat

No net insider activity over 90 days

Short interest Rising

12.58% of float · ▲ +5.5% MoM · 15.1 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

346 holders — near 3-yr high, broad support

Price context

position in its 52-week range

Range low $64 Now $140 · 80% Range high $159

vs 200-day avg +26% vs 50-day avg -3%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
PTGX Protagonist Therapeutics, Inc this stock	$9.18B	+60.4%	-89.4%	137.7	12.6%
VRTX Vertex Pharmaceuticals Inc / Ma	$133.37B	+11.3%	+46.2%	30.7	1.9%
REGN Regeneron Pharmaceuticals, Inc.	$81.13B	-4.8%	+20.8%	19.5	2.5%
MRNA Moderna, Inc.	$79.40B	+544.3%	+4.3%	—	8.2%
CSLLY Csl Ltd	$61.25B	—	—	—	0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

346

% held: 118.1%
Reported: 2 of 346
Top holder: BlackRock, Inc.

Held Float

View

Held by Funds

Fund positions

400

View

Short & Settlement

Short Interest Rising

Shares short

8.1M

Days to cover: 15.1d
Change: +427.7K sh

View

Short Volume

Short vol %

65%

As of: Oct 2, 2026

Short Total

View

Fails to Deliver

FTD shares

29.0K

Value: $4.2M
As of: Sep 9, 2026

View

Off-Exchange

Off-exchange %

47.3%

Week of: Aug 24, 2026

Off-exch Lit

View

Financials

Net income (FY)

$-130.1M

EPS diluted: $-2.05

View

Filings

SEC Filings

Latest

8-K

Filed: Aug 5, 2026
This year: 11

View

Proposed Sales

Value

$8.3M

Shares: 58.6K
Filed: Sep 30, 2026

View

Earnings & Events

Webcasts

Last webcast

Sep 10, 2026

View

Performance

	5D	20D	120D	MTD	YTD
PTGX	-1.3%	-5.9%	+43.6%	-0.6%	+60.4%
SPY	-0.2%	-0.5%	+12.2%	+0.9%	+12.9%
vs SPY	-1.1%	-5.4%	+31.4%	-1.5%	+47.5%

Key facts CIK 1377121 CUSIP 74366E102 13F (30d) 8 filings 8 filers Visit website Investor relations

PTGX · Protagonist Therapeutics, Inc

Price & Indicators

Up next

Metrics snapshot

Equibles Rating

Technicals

Key metrics

Versus peers

At a glance

Performance